Protagonist Therapeutics, Inc. PTGX
Set alert
As of Nov 2, 2:37 PM ET
- YTD
- +60.99%
- 1 year
- +78.85%
- Open
- 145.74
- Prev close
- 144.85
- Mkt cap
- 9.09B
- Vol
- 184.20K
- Avg vol
- 645.05K
- EPS
- 1.03
- P/E
- 136.34
- Div yield
- 0.00%
More statistics
- Low
- 140.42
- High
- 146.01
- Forward P/E
- -1459.30
- Beta
- 1.52
- Short ratio
- 12.29
- Inst. own
- 119.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 143.05
- 200-d avg
- 116.32
- 1y target
- 178.57
News
4 days ago zacks.com
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago zacks.com
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 days ago zacks.com
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
1 week ago seekingalpha.com
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs, robust liquidity, and a $300 million buyback. PTGX secured lucrative back-end royalties and milestones…
-
1 week ago benzinga.com
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160
TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.
2 weeks ago defenseworld.net
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
2 weeks ago defenseworld.net
Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)
Genelux (NASDAQ: GNLX - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
2 weeks ago zacks.com
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near…
2 weeks ago benzinga.com
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.28% on an annualized basis producing an average annual return of 19.88%. Currently, Protagonist…
-
3 weeks ago benzinga.com
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $184.
-
3 weeks ago benzinga.com
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.
1 month ago benzinga.com
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 20.58%. Currently, Protagonist…
1 month ago defenseworld.net
Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review
MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
1 month ago defenseworld.net
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in Stock
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 63,548 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an…
1 month ago defenseworld.net
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $7,902,361.38 in Stock
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,174 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The shares were…
1 month ago defenseworld.net
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX
Hsbc Holdings PLC raised its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 1,260.9% during the second quarter, according to its most recent filing with the Securities and Exchange…
1 month ago seekingalpha.com
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
-
1 month ago benzinga.com
Protagonist Therapeutics Announces $300M Buyback Plan
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its…
1 month ago accessnewswire.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the…
2 months ago accessnewswire.com
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.
2 months ago benzinga.com
Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor…
-
2 months ago benzinga.com
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.
2 months ago seekingalpha.com
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
2 months ago marketbeat.com
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia…
2 months ago benzinga.com
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
2 months ago fool.com
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
J&J's portfolio primarily includes small biotech and medtech companies. Its largest investment is in the company in its portfolio with the largest market cap.
2 months ago accessnewswire.com
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit…
2 months ago defenseworld.net
Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX
Bamco Inc. NY bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission.…
2 months ago accessnewswire.com
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in…
-
2 months ago benzinga.com
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
2 months ago benzinga.com
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $118 to $173.
2 months ago benzinga.com
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.
-
2 months ago benzinga.com
Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186
Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.
-
2 months ago benzinga.com
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over…
-
3 months ago benzinga.com
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $119 to $151.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $121 to $145.
4 months ago benzinga.com
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.
4 months ago benzinga.com
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
4 months ago benzinga.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.
-
5 months ago benzinga.com
Protagonist Therapeutics To Present Four Abstracts On Rusfertide In Polycythemia Vera At 2026 European Hematology Association Congress In Sweden
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology…
-
6 months ago benzinga.com
Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $137
Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $120 to $137.
-
6 months ago benzinga.com
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $118
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $118.
-
6 months ago benzinga.com
Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.42) by 111.9 percent. This is a 126.32 percent increase over…
-
6 months ago benzinga.com
Protagonist Therapeutics Exercises Opt-Out Of Rusfertide 50:50 Profit And Loss Sharing Arrangement With Takeda, Eligible For Up To $400M In Opt-Out Payments
By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible to receive up to $400 million in opt-out payments, consisting of $200 million payable upon the…
-
6 months ago benzinga.com
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $121
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $110 to $121.